About us

Leader in the development, production
and commercialisation of pharmacogenetics
tests for cancer precision medicine.

Our group

Diatech Pharmacogenetics, in order to compete better on the molecular medicine market, has created a network of the following companies:

Diatech Labline s.r.l. a socio unico established in 2011, focused on the distribution of products and reagents for molecular biology and cellular biology labs.

www.labline.it

BiMind s.r.l. offers twenty years of experience in Information Technology, a strong passion for technology declined in software design, which goes beyond the mere professional field. In the course of its growth, the company has focused its core business in the healthcare sector, developing a deep specialisation in specific clinical care areas, such as onco-haematology.

www.bimind.it

FloNext srl the mission of the spinoff is to develop and discover breakthroughs and developments of innovative molecules for the treatment of human diseases, including chronic ones.

www.flonext.net

LionDX srl LionDx develops and markets molecular tests for Clinical Microbiology with a particular focus on Fungal diagnostics. Within our extensive range of Real-Time PCR tests, LionDX highlights unique kits on the market for the detection of Candida auris and many other Candida species.

www.liondx.com

Quality in our products

Competition in a high technology market requires strict quality control of all commercial and scientific parameters.

Diatech Pharmacogenetics has reached this goal by achieving:

Profile

Diatech Pharmacogenetics is the Italian leader in the development, production and commercialisation of pharmacogenetics tests for cancer precision medicine.
Founded in 1996, Diatech Pharmacogenetics has sustained constant organic growth over the years and now owns more than 70% of the Italian molecular diagnostic market and it is rapidly growing worldwide; to date, more than 20.000 diagnostic tests have been performed using its solutions and every year Diatech Pharmacogenetics reinvests 20% of it revenues in R&D.
Diatech Pharmacogenetics is able to take pharmacogenetics tests from idea to market on a variety of platforms, from real-time PCR to barcoded microarrays, mass-spectrometry and next generation sequencing, supplying all reagents, instruments, materials and support necessary. Its complete solutions guide diagnostic operators from sample extraction, quality control, molecular assay to bioinformatic analysis and report.
The latest products launched include a liquid biopsy cfDNA extraction kit, a real-time PCR system with all reagent provided in a dry and stable format, micro-satellite instability assays and an end-to-end NGS solution that works on both Illumina and IonTorrent platforms.
All Diatech products are developed under EN ISO 9001 and EN ISO 13485 and have been designed, developed and validated in accordance with the Directive 98/79/EC on in vitro diagnostic medical devices (CE-IVD).

Scientific Board

An ambitious project realized thanks to the membership of illustrious names and prestigious personalities, who will help shape the future of the Company, guiding its scientific and strategic choices, aimed at the improvement of an increasingly high-performance precision oncology diagnostics